克癌新汤剂联合FOLFOX方案治疗进展期胃癌疗效观察  

Observation of efficacy of Ke--ai--xin decoction combined with FOLFOX4 regimen in treatment of advanced Gastric cancer

作　　者：姚健[1] 刘明华[2] 王顺和[1] 余利坚[1] 任美萍[2] 李蓉[2] 肖顺汉[2] 

机构地区：[1]四川泸州市人民医院,646000 [2]四川泸州医学院药学院,646000

出　　处：《医学信息（下旬刊）》2011年第1期44-45,共2页Medical information

基　　金：四川省教育厅重点项目（2005A076）

摘　　要：目的：观察克癌新汤剂联合FOLFOX4方案治疗进展期胃癌的临床疗效及不良反应.方法：将49例患者随机分为克癌新汤剂组25例和对照组24例,两组均应用FOLFOX4方案化疗,克癌新汤剂组同时加用克癌新汤剂,治疗4周期后评价疗效及毒副反应.结果：克癌新汤剂组有效率为64.00% （16/25）,对照组为41.67% （10/24）,差异有统计学意义（P＜0.05）;克癌新汤剂组Kamofsky评分提高高于对照组,且能提高CD3＋、CD4＋ 和CD4＋/CD8＋,改善化疗后机体的免疫功能（P＜0.05）;;两组主要不良反应恶心呕吐、骨髓抑制、腹泻、神经毒性和脱发等指标的差异具有显著性（P＜0.05）.结论：克癌新汤剂联合FOLFOX4方案治疗进展期胃癌,在疗效、生存质量方面优于单用F0LF0X4方案,且不良反应轻.Objective; To evaluate the efficacy of Ke--ai--xin decoction combined with FOLFOX4 in treatment of advanced Gastric cancer. Meth- ods： 49 patients were randomly divided into treatment group（n=25）and control group（n= 24）. The treatment group was treated with Ke--ai--xin decoction and FOLFOX4. The control group was treated with FOLFOX4 only. Results： The response rates were 64.00% and 41.67% respectively in two groups （ P 〈0. 05）. There was difference in improving the quality of life and immune function between two groups （ P〈0.05）. Adverse reac- tions of two groups also .had significant dlflference included： nausea and vomiting,, myelosuppression, dlarrhea, neumtoxicity and alopeciap （ P〈0. 05）. Conclu3ion ： Ke--ai--xin decoction combined with FOLFOX4 regimen is more effective in treatment of advanced Gastric cancer with less toxicities.

关 键 词：克癌新汤剂 进展期胃癌 FOLFOX4方案 

分 类 号：R735.2[医药卫生—肿瘤]